PANCREAZE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PANCREAZE (PANCREAZE).
Pancreatic enzyme replacement therapy; provides lipase, amylase, and protease to digest fats, carbohydrates, and proteins in the duodenum, compensating for pancreatic exocrine insufficiency.
| Metabolism | Not systemically absorbed; acts locally in the gastrointestinal tract; proteolytic degradation in the gut. |
| Excretion | Not applicable; PANCREAZE (pancrelipase) is a digestive enzyme replacement. It works locally in the gastrointestinal tract and is not absorbed systemically. Elimination occurs via fecal excretion of undigested enzymes and breakdown products. |
| Half-life | Not applicable; as a locally acting enzyme, systemic half-life is not relevant. Enzymes are degraded in the GI tract and excreted in feces. |
| Protein binding | Not applicable; minimal systemic absorption, thus protein binding is not relevant. |
| Volume of Distribution | Not applicable; not absorbed systemically, so Vd is not defined. |
| Bioavailability | Oral: Not absorbed; acts locally in the GI tract. Bioavailability is not measurable as systemic exposure is negligible. |
| Onset of Action | Oral: Onset of fat digestion occurs within 30 minutes of administration, corresponding to gastric emptying and mixing with chyme. |
| Duration of Action | Oral: Duration of enzyme activity depends on transit time through the small intestine, typically 1-2 hours postprandially. Clinical effect lasts throughout the digestive period. |
500 to 2500 lipase units/kg per meal, orally, typically 25000 to 75000 lipase units per meal.
| Dosage form | CAPSULE, DELAYED RELEASE |
| Renal impairment | No specific dosage adjustment required for renal impairment. |
| Liver impairment | No specific dosage adjustment required for hepatic impairment. |
| Pediatric use | Infants: 2000 to 4000 lipase units per 120 mL formula or per feeding; Children: 1000 to 2500 lipase units per kg per meal. |
| Geriatric use | Initiate at low end of dosing range (e.g., 500 lipase units/kg per meal) and titrate based on clinical response and tolerance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PANCREAZE (PANCREAZE).
| Breastfeeding | Pancrelipase is a large protein enzyme complex that is not expected to be excreted into breast milk in significant amounts due to its molecular size and degradation in the gastrointestinal tract. No M/P ratio is available. It is considered compatible with breastfeeding. |
| Teratogenic Risk | Pancrelipase is not absorbed systemically and is unlikely to pose a teratogenic risk. No fetal risks have been reported in any trimester. Available data from postmarketing reports and literature reviews do not indicate an increased risk of major birth defects, miscarriage, or adverse fetal outcomes. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to porcine proteins","Acute pancreatitis","Acute flare of chronic pancreatitis"]
| Precautions | ["Fibrosing colonopathy reported with high doses in cystic fibrosis patients; avoid exceeding recommended dosage","Risk of hyperuricemia due to purine content; monitor uric acid in predisposed patients","May cause irritation of oral mucosa; do not crush or chew capsules","Contains porcine-derived enzymes; potential for allergic reactions"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal nutritional status, weight gain, and symptoms of malabsorption (e.g., steatorrhea, abdominal pain). No specific fetal monitoring is required as there is no known fetal risk. |
| Fertility Effects | No known effects on fertility. Pancrelipase does not alter hormone levels or reproductive function. |